# Clinuvel Pharmaceuticals (CUVL) — Earnings

CUVL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cuvl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.35 |
| EPS estimate | $0.35 |
| EPS surprise | −0.97% |
| Revenue surprise | +3.63% |
| Revenue | $43.8M |
| Revenue estimate | $42.2M |
| Reported | Aug 27, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1290877/000149315226040352/form6-k.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2026 | Aug 27, 2026 | $0.35 | $0.35 | -0.97% | $42.2M | $43.8M |

## Frequently Asked Questions

### When did Clinuvel Pharmaceuticals (CUVL) last report earnings?

Clinuvel Pharmaceuticals last reported on Aug 27, 2026, covering fiscal Q4 2026.

### Did CUVL beat earnings estimates?

No. Clinuvel Pharmaceuticals reported EPS of $0.35 for Q4 2026 against a $0.35 estimate — a 0.97% miss.

### How much revenue did CUVL report last quarter?

Clinuvel Pharmaceuticals reported $43.8M in revenue for Q4 2026, against a consensus estimate of $42.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).